Background: Protease inhibitor 2 derived from potato (PI2) is claimed to reduce appetite and food intake, stimulate the satiety hormone cholecystokinin (CCK) and lower postprandial glucose peaks when taken before a meal. However, current literature is inconclusive with regard to its efficacy and mechanism. Furthermore, the potential effect of PI2 on appetite motivational ratings without an immediately following meal has not previously been reported. Objective: To comprehensively test the effects of 30 mg PI2 in a minidrink on appetite ratings, subsequent food intake, and plasma CCK and glucose responses. Design: Minidrinks with or without 30 mg PI2 were compared in three separate substudies (A, B and C), each using a two-way, placebo-controlled, balanced-order, cross-over design and 23 or 24 subjects (mean over groups: body mass index 25.0 kg m À2 , range 22.5-30.7 kg m À2 ; age 41.3, range 18-62 years). The minidrink was given (A) 120 or (B) 30 min before an ad libitum lunch or (C) 30 min before a fixed lunch. Study parameters were self-reported satiety (substudies A and C), ad libitum meal intake (substudies A and B), and (in an n ¼ 12 subset) plasma CCK and blood glucose in all substudies. All results were analyzed using analysis of covariance. Protease-inhibitory activity of the PI2-containing minidrinks was assessed under simulated gut conditions. Results: PI2 did not differ from control for any study parameters, in any substudy, despite confirmation of the inhibitory activity of PI2. Conclusions: In this study protease inhibition using PI2 in a minidrink at a dose of 30 mg, as commercially used, had no (functional) efficacy on a range of behavioral and physiological appetite and intake control measures.
Introduction
Inhibition of digestive proteases has been proposed to increase the triggering of several nutrient-sensing mechanisms in the gastrointestinal tract, potentially generating enhancement of signals for reduced appetite and food intake. 1 Accordingly, protease inhibitors have been suggested as putative functional agents for appetite control. 2 Several food ingredients and supplements are already marketed on the basis of this concept.
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Scientific evaluations of the effect of protease inhibition on appetite or food intake are, however, very limited and inconsistent. The current literature in humans is limited to studies of a specific class of protease inhibitors extracted from potatoes, 'potato protease inhibitor 2' (PI2). One full paper has been published 6 reporting reductions in food intake after consumption of 1500 mg potato extract (PI2 content not explicitly stated). Two abstracts 7, 8 and one patent 9 indicate reduction of appetite after intake of 30 mg PI2. However, effects were not seen in all appetite scales. One other full paper reported that 60 mg PI2 decreased gastric emptying and increased glucose tolerance. 10 However, these studies differed substantially in their design (dose, timing of dose administration, food matrix, test meal, so on) and results so far have been inconsistent for many of the studied parameters. Furthermore, the potential effect of PI2 on appetite motivational ratings without an immediately following meal is currently unknown.
The putative effects of PI2 or other protease inhibitors on appetite control are suggested to be mediated by a slowing of the protease-mediated degradation of cholecystokin-releasing factor (CCK-RF). CCK-RF is secreted from enterocytes into the lumen of the small intestine in response to food intake, and stimulates secretion of the appetite-suppressing hormone CCK into plasma. 1 Therefore, inhibition of proteases could lead to more and prolonged CCK release and action. Although this evidence is mainly based on animal research, 1 three studies with humans (two abstracts, one patent) indicate increased postprandial CCK plasma concentrations after PI2 administration, although with some inconsistencies with regard to time points and dose response. [10] [11] [12] The aim of our study, therefore, was to investigate in healthy subjects whether addition of 30 mg of PI2 to a minidrink results in activation of CCK release before or during food ingestion, and in a reduction of appetite or subsequent food intake. Three substudies were designed to cover a range of intake scenarios and conditions.
Subjects and methods

Subjects
For each of three substudies, 24 male and female subjects were recruited from the local area of Leatherhead, UK, starting in November 2008. In all, 22 subjects participated in all three substudies. Selection criteria were as follows: age 18-60 years, body mass index (kg m À2 ) X21 and p32.0, apparent health (measured by a questionnaire) and no use of medicines judged likely to influence the study results. To focus on potential responsiveness to physiological signals only normal and low-restraint eaters were included. 13 Any participant with a tendency to contract diagnosable eating disorders (anorexia nervosa or bulimia) was also excluded. 14 
Study design
The study consisted of three separate two-arm substudies, A, B and C, each having a fully randomized double-blind crossover balanced design with two periods and two treatments (either the treatment drink or the control drink described below). Of the 24 participants in each substudy, 12 were asked to participate in the blood measurements as well. Each substudy was carried out in a 2-week period, in which each participant visited the test facility on the same week day; that is, a 1-week washout period between treatments during the substudy. There was 1 week washout between the substudies. Substudy A was designed to study the effect of PI2 in a minidrink consumed between meals on appetite and ad libitum meal intake. The minidrink was given at 1100 hours. Satiety (from 1100 till 1300 hours) was the main study parameter. Substudy B was designed to study the effect of PI2 in a minidrink consumed shortly before a meal on subsequent ad libitum meal intake. The minidrink was given at 1130 hours, and the ad libitum meal at 1200 hours. Meal intake was the main study parameter. Substudy C was designed to study the effect of PI2 in a preload minidrink on appetite when followed by a standard meal. The minidrink was given at 1130 hours, the standard meal at 1200 hours. Post-meal satiety (from 1200 to 1600 hours) was the main study parameter. The specific scales used and the composition of the test meals are described below.
All substudies were carried out by Leatherhead Food International, Leatherhead, UK, and the protocol was approved by the East Kent Local Research Ethics Committee, East Kent, UK.
Test foods
In all studies a SlimÁFast Optima ready-to-drink shake (325 ml, 190 kcal; Unilever, Englewood Cliffs, NJ, USA) was given as standard breakfast at 0800 hours. Participants who were not providing blood samples were then allowed to leave the unit if they wished. In substudy A participants were provided with the minidrink to consume when prompted at 1100 hours by the electronic appetite scoring system described below. Participants were instructed to return to the unit by 1230 hours (substudy A) or 1100 hours (substudies B and C).
All treatments consisted of the consumption of a minidrink. Test foods consisted of the following:
1. Minidrink þ 600 mg microcrystalline cellulose (control) 2. Minidrink þ 600 mg potato extract (treatment)
The minidrink contained 2 g high-oleic rapeseed oil, 3 g sugar, 4.2 g peach puree, 1.25 g pectin and 7.5 g whey protein isolate. Potato extract (Slendesta, Kemin Health Inc., Des Moines, IA, USA) or control was incorporated into the drinks before the delivery to the test facility. Potato extracts are standardized for PI2 content on the basis of their PI2 content using an enzyme-linked immunosorbent assay with a PI2-specific antibody defined by their molecular entity. The 600 mg potato extract contained 30 mg PI2 and microcrystalline cellulose. The control formula contained the same ingredients but with the extract replaced by microcrystalline cellulose. For more details, see Table 1 . The 30 mg PI2 dose was chosen as this is the level used commercially and allowed by the Food and Drug Administration for use in foods. Protease inhibition, appetite and food intake HPF Peters et al
The stability and activity of PI2 in the treatment formula was confirmed by the supplier using a specific in vitro trypsin inhibition assay (data not shown). The inhibitory activity of the minidrink toward all relevant proteases (chymotrypsin, trypsin, elastase) was also confirmed under simulated gut conditions (see Supplementary Figure S5 ).
Subjective feelings of appetite
In all substudies, self-assessments of feelings of appetite were collected every 30 min from breakfast (at 0800 hours) until the end of the day (at 1600 hours), except for the time period just before and after the meal, during which scores were measured every 15 min (for example, every 15 min from 1100 to 1300 hours in substudy A and from 1130 to 1300 hours in substudies B and C). Ratings were made on a handheld device by means of a mark on a 64-mm line using an electronic visual analog scale 15 anchored at the low end with the most negative or lowest intensity feelings (for example, not at all), and with opposing terms at the high end (for example, very high), as described by Flint et al. 16 The scale items were 'appetite for a meal', 'appetite for a snack', 'how much do you want to eat', 'fullness', 'hunger' and 'thirst'.
Ad libitum meal intake Energy intake was measured either 120 min (substudy A, at 1300 hours) or 30 min (substudy B, at 1200 hours) after consumption of the minidrink by providing an ad libitum meal consisting of a single dish in very large quantities. Lunch during substudies A and B consisted of 1250 g macaroni Bolognese (macaroni, minced pork meat and Bolognese tomato sauce providing (per 100 g) 439 kJ, 4 g protein, 5 g fat, 9 g carbohydrates; energy density was 1.05 kcal g
À1
). Food intake from this meal was calculated from the difference in the weight of food offered and that remaining. During the meal, participants sat separately in individual booths, and each participant received his or her own tray of (preweighed) foods (large amounts).
In substudy C all participants received the same macaroni Bolognese lunch 30 min after ingestion of the minidrink, but amount was fixed at 300 kcal (286 g).
Blood sampling and measurements
Blood samples for CCK and glucose analysis were collected from 12 out of 24 participants in each substudy before and at regular intervals after minidrink ingestion. Blood was sampled from a flexible intravenous cannula that was inserted into an antecubital vein 15 min before the sampling started on each test day. A volume of 5 ml blood per sample was collected in a Vacutainer tube containing K 3 EDTA (Greimer Bio-one, Kremsmuenster, Germany) as anticoagulant and the protease inhibitor Trasylol (aprotinin LINCO Research, MO, USA; 500 KIU ml À1 of blood).
The samples were put on ice water immediately after sampling.
A 300-ml aliquot was removed from each blood sample collected, placed into a microvette tube containing lithium heparin, and immediately cooled and stored in an ice bath for further analysis for plasma glucose concentration at the study site. The remainder was centrifuged (2000 g, 15 min at 4 1C) within 30 min. The plasma was frozen within 2 h and stored at À70 1C until further analysis. Plasma was analyzed for CCK and glucose. For CCK analysis, frozen plasma samples were transported to a designated laboratory (TNO Zeist, Zeist, The Netherlands) after completion of each substudy. Plasma CCK-8 concentrations were measured using a commercial human RIA kit (EuroDiagnostica, Malmis, Sweden) as described previously. 17 This CCK-8 assay system has been optimized to reach a sensitivity of 0.05 pmol l
À1
, with no cross-reactivity toward gastrin-17 and sulfated gastrin. The intra-assay coefficient of variationwas 8.9% at a concentration of 0.84 pmol l À1 and 4.9% at a concentration of 1.98 pmol l
. 17 For glucose measurements, plasma was separated by centrifugation (3000 r.p.m., 15 min at 4 1C) within 60 min after sampling, then frozen within 2 h and stored at À20 1C. Analysis was carried out in duplicate using an YSI 2300 Stat Plus glucose analyzer (YSI, Yellow Springs, OH, USA).
Background diet, physical activities and other measurements
The participants were encouraged to minimize changes in composition of their habitual diet and physical activity during the period of the study. They were asked to avoid alcohol intake and sports activities the day before the test day. Dietary intake of the evening meal and all other consumption till 2200 hours had to be recorded and repeated on the day before the following test day. Eating and drinking after 2200 hours on the evening before each test day was not allowed except for noncaloric drinks. Time and amount of noncaloric drink consumption were recorded and repeated the evening before the following test day.
On the morning of the test, the participants were asked to arrive in a fasting state at the test facility at 0730 hours. During each test day, only noncaloric drinks (water, coffee or tea without milk or sugar) were allowed until 0700 hours, but had to be recorded and repeated on the other test days. Mode of transportation was also recorded. During the first test day the time and amount of coffee or tea (without milk or sugar) and water consumption were recorded and repeated on the following test day.
Statistical analyses
In earlier studies from our research center, a withinparticipant variance of about 85 mm min for the areaunder-the curve (AUC) has been consistently observed for appetite ratings. On the basis of this variance, a confidence limit of 0.05 and a power of 0.8, 18 participants were required for appetite measurements, and 24 participants Protease inhibition, appetite and food intake HPF Peters et al were selected to allow for some dropouts. A 12-participant subset was used to measure plasma glucose and CCK. This group size (n) of 12 was the result of a power calculation on the basis of a predicted difference in the CCK release of at least 0.5 pM, a power of at least 0.9 and an overall a of 0.05. Results are presented as least-squares means with standard error (s.e.), unless otherwise specified. The 64-mm appetite electronic visual analog scale scores are transformed and expressed on a 100-mm basis, and as incremental cumulative AUC, using the values at t ¼ 0 min (just before consumption of the minidrink) as a covariate. The AUC was calculated using the trapezoid rule.
All parameters were analyzed using analysis of covariance with subjects as blocks and treatment as factor. A Tukey test was used to compare each treatment with the control. The analysis was carried out per time point and also for AUC by using SAS (version 9.3, PROC MIXED; SAS Institute, Cary, NC, USA). 
Results
In all, 23 (substudy
Appetite
There were no significant differences between PI2 and control for any appetite-related measures in any of the substudies, based either on single time points or on AUC. Given that all line scales produced similar nonsignificant results, only hunger is shown as a representative example (Figure 1 ).
Food intake
Food intake was not affected by treatment in either of the two substudies in which this was measured (control vs PI2: substudy A: 616 vs 639 kcal, s.e. ¼ 45; substudy B: 591 vs 595 kcal, s.e. ¼ 60).
Plasma CCK and blood glucose
Owing to one drop-out in each of substudies A and B, blood samples were collected from 11 participants in these substudies and from all 12 participants in substudy C. Plasma CCK concentrations were not affected by treatment in any substudy, represented as individual time points or as AUC (as an example, see Figure 2 for substudy A; curves for substudy B and C are shown as Supplementary  Figures S1 and S2 ).
Blood glucose concentrations were also not affected by treatment in any substudy, represented as individual time points or as AUC (as an example, see Figure 3 for substudy A; curves for substudies B and C are shown as Supplementary  Figures S3 and S4 ).
Discussion
In a structured approach using three different study designs, we have shown that a commercially available digestive Protease inhibition, appetite and food intake HPF Peters et al protease inhibitor at the dose used commercially and consumed before or between meals does not meaningfully affect plasma CCK concentrations, subjective appetite measures or ad libitum energy intakes. Given that the proteaseinhibition activity of the test material was confirmed under simulated gastrointestinal conditions, the results strongly suggest that digestive protease inhibition per se is not a viable intervention route to influence meal intake and appetite.
The effect of digestive protease inhibition was studied in this study using the protease inhibitor fraction PI2 isolated from potato protein. Although the general principle of protease inhibition itself has not been tested yet, a few studies in humans have investigated the functional effects of the potato protease inhibitor PI2 specifically.
The only previous study on the effect of PI2 on food intake in humans 6 showed a meal intake reduction of 17.5% when 1500 mg potato protein extract was given in a soup 5 min before an ad libitum lunch. The activity of PI2 in this extract and CCK data were not reported. If the PI2 concentration of that extract was similar to the extract used in this study (30 mg PI2 in 600 mg extract), then this would equate to 75 mg PI2. In our substudy B, which was in its design most similar with that study, we found no effects on ad libitum food intake or plasma CCK concentrations, although the timing (30 vs 5 min before the meal) and probably also the dose (30 mg vs the estimated 75 mg) were different between the studies. The effect of PI2 on appetite has been reported in two abstracts 7, 8 and one patent. 9 Spiegel et al. 8 gave 21 females protease inhibitors from potato (amount of protease inhibitor not specified) in a drink (237 ml, 80 kcal) 15 min before lunch, before and after 4 weeks of dieting. Appetite ratings were not affected by PI2 before dieting, whereas after dieting the reported fullness was significantly higher (71.0 vs 65.6) and hunger significantly lower (10.5 vs 15.4) after intake of PI2 compared with control. Other appetite parameters were not reported. Vasselli et al. 7, 9 gave 30 mg PI2 in a drink (237 ml, 80 kcal) 15 min before lunch and found that PI2 decreased hunger by 30% in the three and a half hours following the meal (Po0.05). Fullness ratings were reported to be 'significantly greater starting 3 h after meal'. However, four other hunger-related visual analog scale scores did not differ between PI2 and control. Using a similar design and PI2 dose in substudy C (30 mg PI2 in a drink 30 min before a standard lunch), we found no effect on appetite ratings or CCK. The design used in substudy A, that is, assessing the effect of PI2 on appetite without giving a subsequent (standard) meal, has not been used in any previous study. However, in these conditions, PI2 also did not affect appetite ratings or CCK.
The results from this study clearly show that in these different study designs PI2 is not efficacious for food intake reduction and hunger control. These results could be potentially attributed to an absence or loss of proteaseinhibitory activity. Successful application of protease inhibitors to stimulate CCK release in humans most likely requires a combination of trypsin, chymotrypsin and elastase inhibition, 18 and inhibition of trypsin activity alone is probably not sufficient. [18] [19] [20] Furthermore, the inhibitors have to be resistant to the enzymatic activity of human gastric proteases. Our in vitro data show that PI2 indeed inhibited the action of trypsin, chymotrypsin and elastase under simulated gastric conditions, and data supplied by the manufacturers also confirmed that both the amount and inhibitory activity of PI2 in the product were not affected by processing of the minidrink. Other possible explanations of the lack of effect of PI2 here could be related to either the food (matrix) effect of the minidrink itself or of the meal following the drink, or the timing of PI intake and dose.
As noted, the putative action of PI2 is suggested to be mediated by a reduced rate of CCK-RF degradation by proteases, leading to more or prolonged CCK release and action. However, the mechanism by which enterocytes are stimulated to release CCK-RF is not well understood. It is 
Control PI2
Figure 3 Blood glucose concentrations (least-square means ± s.e.) during sub-study A (n ¼ 11) after consumption of a minidrink with or without PI2. There were no statistically significant differences between treatments (by analysis of covariance) based on single time points or on AUC.
Protease inhibition, appetite and food intake HPF Peters et al possible, though not experimentally confirmed, that food components themselves trigger CCK-RF release directly. The mechanisms that lead to CCK secretion from enteroendocrine cells are also not fully understood, but include in all cases direct effects of digestion products. 21 However, other nutritive and non-nutritive compounds can also trigger directly CCK release from enteroendocrine cells through the activation of specific receptors, independent of CCK-RF, [22] [23] [24] and this effect is potentially bigger than the CCK-RF effect. Therefore, CCK secretion in response to meal intake is mediated by complementary and overlapping systems. Moreover, a number of complementary systems are involved in appetite regulation, which involve inter alia other appetite hormones (for example, glucagon-like peptide-1 and peptide YY) and neural activation. Protease inhibitors such as PI2 would therefore be interacting with only one part of the CCK release system and overall appetitesignaling network. The dose of 30 mg PI2 used here was claimed to be effective in other appetite studies, [7] [8] [9] although in one case 6 a higher dose was used (assuming that the PI2 concentration of that extract was similar to the extract used in our study). We choose to test a dose of 30 mg PI2, as this dose is recommended by the manufacturer, safe and claimed to have appetite effects.
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The compositions of the minidrink and of the meal consumed afterwards were similar to those used in previous PI2 studies, so these should not explain the absence of a PI2 effect in this study. [6] [7] [8] Nevertheless, the PI2-induced effects, if any, were clearly too small to exceed drink-and mealinduced effects on appetite. This is underpinned by the absence of any PI2 effect on minidrink-and test mealinduced changes on plasma CCK. 6 On the basis of the hypothesis that PI2 exerts its effects by increasing and prolonging food-induced CCK release, the timing of PI2 intake relative to the meal could have an influence on apparent efficacy. As plasma CCK concentrations generally peak around 30 min after a meal, we decided to give PI2 30 min before the meal. Indeed, CCK concentrations were still elevated after 30 min in all three substudies, suggesting that induction of CCK activity (by the minidrink) was still ongoing when the meal was ingested in substudies B and C. Although CCK concentrations were not very different between 15, 30 and 60 min after the minidrink, it is possible that giving PI2 at times o30 min before the ad libitum or standard meal might produce different behavioral outcomes. This remains to be tested. On the basis of these considerations, we conclude that the protease inhibitor PI2, a commercially available digestive protease inhibitor, shows no evidence of functional efficacy in a minidrink in a range of behavioral and physiological measures and test designs at the dose used commercially. Although it is still possible that this or other protease inhibitors may affect appetite in other food or supplement formats or conditions of use, significant effects on subjective appetite ratings and food intake were clearly not apparent in this study.
